Oncolytic Reovirus and Immune Checkpoint Inhibition as a Novel Immunotherapeutic Strategy for Breast Cancer
Author:
Funder
Canadian Breast Cancer Foundation
Publisher
MDPI AG
Subject
Cancer Research,Oncology
Link
http://www.mdpi.com/2072-6694/10/6/205/pdf
Reference54 articles.
1. Molecular characterization and targeted therapeutic approaches in breast cancer
2. Cancer statistics, 2018
3. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study
4. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
5. Tumor-Infiltrating CD8+ Lymphocytes Predict Clinical Outcome in Breast Cancer
Cited by 50 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Intratumoral delivery of immunotherapy to treat breast cancer: current development in clinical and preclinical studies;Frontiers in Immunology;2024-05-13
2. New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy;Frontiers in Immunology;2024-03-21
3. Oncolytic virus-based combination therapy in breast cancer;Cancer Letters;2024-03
4. Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell–Based Immunotherapies;Cancer Immunology Research;2024-01-09
5. Unveiling Strategies to Conquer Virus-Induced Breast Cancer Drug Resistance;Overcoming Breast Cancer Therapy Resistance;2024
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3